Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, Martínez L, de la Llana FG, Sánchez-Villegas J, Alvarez H, Mariño A, Lluch JF, Martínez-Pérez MA, Marín J, Ruiz-Mateos E, Leal M. Genebat M, et al. Among authors: vera f. Antiviral Res. 2014 Apr;104:59-61. doi: 10.1016/j.antiviral.2014.01.019. Epub 2014 Jan 31. Antiviral Res. 2014. PMID: 24491797
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J; GESIDA 44/04 SIMPATAZ Study Group. Rubio R, et al. HIV Med. 2010 Oct 1;11(9):545-53. doi: 10.1111/j.1468-1293.2010.00827.x. Epub 2010 Mar 19. HIV Med. 2010. PMID: 20345884 Free article.
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E. Blanco JR, et al. Among authors: vera f. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1403-204. HIV Clin Trials. 2013. PMID: 24144897
Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC, Alvarez-Ríos AI, Bernal-Morell E, Genebat M, Vera F, Benhnia MR, Bravo-Urbieta J, Galera-Peñaranda C, de Pablo-Bernal RS, Abad-Carrillo MA, Leal M, Ruiz-Mateos E; VIH-GEMUVIH Región de Murcia Study Group. Romero-Sánchez MC, et al. Among authors: vera f. Antiviral Res. 2014 Nov;111:26-32. doi: 10.1016/j.antiviral.2014.08.011. Epub 2014 Aug 27. Antiviral Res. 2014. PMID: 25173576 Clinical Trial.
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR. Pedrol E, et al. Among authors: vera f. HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. doi: 10.1179/1528433614Z.0000000001. Epub 2015 Jan 28. HIV Clin Trials. 2015. PMID: 25777189
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. AIDS Res Ther. 2020 Jul 20;17(1):45. doi: 10.1186/s12981-020-00302-2. AIDS Res Ther. 2020. PMID: 32690099 Free PMC article.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients with HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS cohort. Berenguer J, et al. J Infect Dis. 2024 Apr 1:jiae168. doi: 10.1093/infdis/jiae168. Online ahead of print. J Infect Dis. 2024. PMID: 38557859
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
Troya J, Montejano R, Ryan P, Gómez C, Matarranz M, Cabello A, Vera F, Sepúlveda MA, Santos I, Samperiz G, Bachiller P, Boix V, Barrufet P, Cervero M, Sanz J, Solís J, Yllescas M, Valencia E; GESIDA-8715 Study Group. Troya J, et al. Among authors: vera f. PLoS One. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768. eCollection 2018. PLoS One. 2018. PMID: 29902204 Free PMC article.
169 results